JPRN-jRCT2080221787未知2 期
An open-label, long-term extension study to evaluate the safety, tolerability and efficacy of 12 months of LCZ696 treatment in patients with essential hypertension
ovartis Pharma K.K.0 个研究点目标入组 344 人开始时间: 2012年5月14日最近更新:
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 344
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1. Patients that have successfully completed Core study (JapicCTI-101273) and who, as judged by the investigator, are able to continue in the open-label extension.
- •2. Ability to communicate and comply with all study requirements and demonstrate good medication compliance (>=80% compliance rate) during Core study.
排除标准
- •1. Patients who did not complete Core study.
- •2. Presence of significant protocol violation in Core study.
- •3. Patients who are deemed to be unable to comply with the protocol by the investigator.
研究者
相似试验
进行中（未招募）
1 期
An open label, long-term extension study to evaluate the safety and efficacy of CRN00808 in subjects with acromegaly (ACROBAT ADVANCE)MedDRA version: 20.0Level: PTClassification code: 10000599Term: Acromegaly Class: 100000004860AcromegalyCTIS2024-511921-75-00Crinetics Pharmaceuticals Inc.31
未知
3 期
Venlafaxine ER long-term extension study for major depressive disorderJPRN-jRCT2080221669Pfizer Japan Inc.50
进行中（未招募）
2 期
A 5-year study to test BI 655130 in patients with Generalized Pustular Psoriasis who took part in previous studies with BI 655130Generalized Pustular Psoriasis (GPP)JPRN-jRCT2041210087Taguchi Aya131
进行中（未招募）
1 期
A 5-year study to test BI 655130 in patients with GeneralizedPustular Psoriasis who took part in previous studies with BI655130Generalized Pustular PsoriasisMedDRA version: 21.0Level: LLTClassification code 10037159Term: Psoriasis pustularSystem Organ Class: 100000004858EUCTR2018-003080-56-ESBoehringer Ingelheim España S.A.150
进行中（未招募）
1 期
A 5-year study to test BI 655130 in patients with Generalized Pustular Psoriasis who took part in previous studies with BI 655130EUCTR2018-003080-56-FRBoehringer Ingelheim France101